Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the transaction, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.05, for a total transaction of $1,064,906.25.

Vera Therapeutics Stock Performance

Shares of VERA opened at $42.60 on Monday. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -16.32 and a beta of 1.08. Vera Therapeutics, Inc. has a 12 month low of $14.20 and a 12 month high of $51.61. The firm has a fifty day simple moving average of $45.27 and a 200 day simple moving average of $40.50. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on VERA shares. Wedbush boosted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Scotiabank began coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and an average target price of $59.22.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VERA. Holocene Advisors LP grew its stake in shares of Vera Therapeutics by 8.8% in the third quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock valued at $86,390,000 after buying an additional 158,451 shares in the last quarter. Samlyn Capital LLC lifted its stake in Vera Therapeutics by 90.8% in the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the last quarter. First Light Asset Management LLC lifted its stake in Vera Therapeutics by 130.6% in the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after acquiring an additional 569,590 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Vera Therapeutics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock valued at $44,415,000 after acquiring an additional 20,223 shares during the period. Finally, Logos Global Management LP increased its stake in shares of Vera Therapeutics by 65.2% during the 2nd quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock worth $34,371,000 after purchasing an additional 375,000 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.